COVID-19 Case Fatality Doubled in Heart Transplant Patients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The aim of this study was to assess the clinical course and outcomes of all heart transplant recipients affected by Coronavirus Disease 2019 (COVID-19) who were followed at the leading heart transplant centers of Northern Italy.

The worldwide SARS-CoV-2 pandemic has created unprecedented challenges for public health, demanding exceptional efforts for the successful management and treatment of affected patients. Heart transplant patients represent a unique cohort of chronically immunosuppressed subjects in which SARS-CoV-2 may stimulate an unpredictable clinical course of infection.

Since February 2020, we enrolled all 47 cases (79% male) in a first cohort of patients, with a mean age of 61.8 ± 14.5 years, who tested positive for SARS-CoV-2, out of 2,676 heart transplant recipients alive before the onset of the COVID-19 pandemic at 7 heart transplant centers in Northern Italy.

Results:
-- To date, 38 patients required hospitalization while 9 remained self-home quarantined and 14 died.

-- Compared to the general population, prevalence (18 vs. 7 cases per 1,000) and related case fatality rate (29.7% vs. 15.4%) in heart transplant recipients were doubled.

-- Univariable analysis showed older age (p = 0.002), diabetes mellitus, extracardiac arteriopathy, previous PCI, CAV score, lower GFR, and higher NYHA functional classes were all significantly associated with in-hospital mortality.

-- During the follow-up two patients died and a third patient has prolonged viral-shedding alternating positive and negative swabs.

-- Since July 1st, 2020, there were 6 new patients who tested positive for SARS-CoV-2, 5 patients asymptomatic were self-quarantined, while 1 is still hospitalized for pneumonia.

-- A standard therapy was maintained for all, except for the hospitalized patient.

Conclusively, the prevalence and mortality of SARS-CoV-2 should spur clinicians to immediately refer heart transplant recipients suspected as having SARS-CoV2 infection to centers specializing in the care of this vulnerable population.

Source: https://www.jacc.org/doi/10.1016/j.jchf.2020.10.009
Like
Comment
Share